应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ZYME ZYMEWORKS INC (US)
盘后交易 07-30 16:58:59 EDT
22.71
+0.70
+3.18%
盘后
23.09
+0.38
+1.67%
16:11 EDT
最高
23.00
最低
21.90
成交量
40.29万
今开
22.02
昨收
22.01
日振幅
5.00%
总市值
16.58亿
流通市值
15.59亿
总股本
7,302万
成交额
908.49万
换手率
0.59%
流通股本
6,865万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
财报前瞻|ZYMEWORKS INC (US)本季度营收预计小幅下滑,机构观点偏谨慎
财报Agent · 03:27
财报前瞻|ZYMEWORKS INC (US)本季度营收预计小幅下滑,机构观点偏谨慎
Theravance Biopharma:若交易在特定情况下终止,公司将向Zymeworks支付3250万美元终止费
美股速递 · 06-29
Theravance Biopharma:若交易在特定情况下终止,公司将向Zymeworks支付3250万美元终止费
Theravance Biopharma盘前重挫3.3%,Zymeworks拟以每股17美元现金加或有价值权收购
美股速递 · 06-29
Theravance Biopharma盘前重挫3.3%,Zymeworks拟以每股17美元现金加或有价值权收购
Theravance Biopharma股东将就Ampreloxetine变现净收益的80%获得或有价值权
美股速递 · 06-29
Theravance Biopharma股东将就Ampreloxetine变现净收益的80%获得或有价值权
财报前瞻 |ZYMEWORKS INC (US)本季度营收预计降21.26%,机构观点偏谨慎
财报Agent · 04-30
财报前瞻 |ZYMEWORKS INC (US)本季度营收预计降21.26%,机构观点偏谨慎
Zymeworks公司FRα靶向抗体偶联药物ZW191获美国FDA快速通道资格认定
美股速递 · 03-30
Zymeworks公司FRα靶向抗体偶联药物ZW191获美国FDA快速通道资格认定
财报前瞻|ZYMEWORKS INC (US)本季度营收预计下降69.96%,关注合作收入波动
财报Agent · 02-23
财报前瞻|ZYMEWORKS INC (US)本季度营收预计下降69.96%,关注合作收入波动
Zymeworks(ZYME.US)获LifeSci Capital首次覆盖,给予优于大市评级, 目标价30.00美元。
金融界 · 2025-03-11
Zymeworks(ZYME.US)获LifeSci Capital首次覆盖,给予优于大市评级, 目标价30.00美元。
HC Wainwright & Co.:维持Zymeworks(ZYME.US)评级,由中性调整至中性评级, 目标价由12.00美元调整至13.00美元。
金融界 · 2025-03-11
HC Wainwright & Co.:维持Zymeworks(ZYME.US)评级,由中性调整至中性评级, 目标价由12.00美元调整至13.00美元。
Zymeworks Inc.盘中异动 快速跳水5.08%报11.39美元
市场透视 · 2025-03-10
Zymeworks Inc.盘中异动 快速跳水5.08%报11.39美元
Zymeworks Inc.2024财年实现净利润-1.23亿美元,同比减少3.36%
市场透视 · 2025-03-10
Zymeworks Inc.2024财年实现净利润-1.23亿美元,同比减少3.36%
花旗:维持Zymeworks(ZYME.US)评级,由买入调整至买入评级, 目标价由18.00美元调整至19.00美元。
金融界 · 2025-03-08
花旗:维持Zymeworks(ZYME.US)评级,由买入调整至买入评级, 目标价由18.00美元调整至19.00美元。
Zymeworks Inc.盘中异动 早盘股价大跌7.02%
市场透视 · 2025-03-06
Zymeworks Inc.盘中异动 早盘股价大跌7.02%
异动解读 | ZYMEWORKS INC盘后大跌5.46%,业绩未达预期令市场失望
异动解读 · 2025-03-06
异动解读 | ZYMEWORKS INC盘后大跌5.46%,业绩未达预期令市场失望
赛梅克斯公司第四季度GAAP每股收益$(0.31)不及预期$(0.03),销售额$3103万不及预期$4520万
财报速递 · 2025-03-06
赛梅克斯公司第四季度GAAP每股收益$(0.31)不及预期$(0.03),销售额$3103万不及预期$4520万
Zymeworks Inc.盘中异动 下午盘快速下跌5.00%报12.73美元
市场透视 · 2025-03-04
Zymeworks Inc.盘中异动 下午盘快速下跌5.00%报12.73美元
Zymeworks Inc.盘中异动 早盘快速下挫5.02%
市场透视 · 2025-02-26
Zymeworks Inc.盘中异动 早盘快速下挫5.02%
Zymeworks Inc.盘中异动 早盘急速跳水5.14%
市场透视 · 2025-02-11
Zymeworks Inc.盘中异动 早盘急速跳水5.14%
Zymeworks Inc.盘中异动 快速上涨5.06%报14.96美元
市场透视 · 2025-02-06
Zymeworks Inc.盘中异动 快速上涨5.06%报14.96美元
Zymeworks Inc.盘中异动 早盘股价大涨5.07%
市场透视 · 2025-01-15
Zymeworks Inc.盘中异动 早盘股价大涨5.07%
加载更多
公司概况
公司名称:
ZYMEWORKS INC (US)
所属市场:
NASDAQ
上市日期:
--
主营业务:
Zymeworks Inc.于2022年6月根据特拉华州法律注册成立。该公司是一家全球性生物技术公司,管理着授权医疗资产组合并开发针对癌症、炎症和自身免疫性疾病的新型生物治疗产品线。其战略结合了特许权使用费聚合、战略收购和内部创新,并以其专有的多特异性抗体和抗体药物偶联物技术平台为支撑。
发行价格:
--
{"stockData":{"symbol":"ZYME","market":"US","secType":"STK","nameCN":"ZYMEWORKS INC (US)","latestPrice":22.71,"timestamp":1785441600000,"preClose":22.01,"halted":0,"volume":402867,"hourTrading":{"tag":"盘后","latestPrice":23.09,"preClose":22.71,"latestTime":"16:11 EDT","volume":27839,"amount":632299.662631,"timestamp":1785442287789,"change":0.38,"changeRate":0.016733,"amplitude":0.016733},"delay":0,"changeRate":0.03180372557928211,"floatShares":68645200,"shares":73023061,"eps":-1.365952,"marketStatus":"盘后交易","change":0.7,"latestTime":"07-30 16:58:59 EDT","open":22.02,"high":23,"low":21.9,"amount":9084876,"amplitude":0.049977,"askPrice":23.15,"askSize":86,"bidPrice":22.27,"bidSize":89,"shortable":3,"etf":0,"ttmEps":-1.365952,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1785456000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1493352000000,"exchange":"NASDAQ","adjPreClose":22.01,"preHourTrading":{"tag":"盘前","latestPrice":21.99,"preClose":22.01,"latestTime":"09:29 EDT","volume":796,"amount":17711.467252,"timestamp":1785418199999,"change":-0.02,"changeRate":-0.000909,"amplitude":0.126306},"postHourTrading":{"tag":"盘后","latestPrice":23.09,"preClose":22.71,"latestTime":"16:11 EDT","volume":27839,"amount":632299.662631,"timestamp":1785442287789,"change":0.38,"changeRate":0.016733,"amplitude":0.016733},"volumeRatio":1.268413,"impliedVol":0.4382,"impliedVolPercentile":0.2709},"requestUrl":"/m/hq/s/ZYME","defaultTab":"news","newsList":[{"id":"1182174063","title":"财报前瞻|ZYMEWORKS INC (US)本季度营收预计小幅下滑,机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1182174063","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182174063?lang=zh_cn&edition=full","pubTime":"2026-07-31 03:27","pubTimestamp":1785439635,"startTime":"0","endTime":"0","summary":"ZYMEWORKS INC 将于2026年08月06日发布财报,市场关注公司合作收入节奏与费用控制下的盈利弹性。ZYMEWORKS INC 的收入高度依赖与大型药企的合作与许可安排,本季度市场预计营收为1,801.10万美元,核心变量在于关键合作管线是否触发里程碑。对于ZYMEWORKS INC 而言,若在本季度披露新的合作签约或临床积极进展,可能带来预期差修复;若信息缺失或里程碑延后,短期股价易受情绪面驱动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻|ZYMEWORKS INC (US)本季度营收预计小幅下滑,机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146396391","title":"Theravance Biopharma:若交易在特定情况下终止,公司将向Zymeworks支付3250万美元终止费","url":"https://stock-news.laohu8.com/highlight/detail?id=1146396391","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146396391?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:38","pubTimestamp":1782729520,"startTime":"0","endTime":"0","summary":"Theravance Biopharma Inc. 披露,根据其与Zymeworks Inc.达成的协议条款,若交易在特定情况下被终止,公司将需向Zymeworks支付一笔高达3250万美元的终止费用。\n此项财务安排明确了交易未能完成时的责任归属,为双方的合作设定了清晰的退出机制。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ZYME","TBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136977316","title":"Theravance Biopharma盘前重挫3.3%,Zymeworks拟以每股17美元现金加或有价值权收购","url":"https://stock-news.laohu8.com/highlight/detail?id=1136977316","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136977316?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:04","pubTimestamp":1782727469,"startTime":"0","endTime":"0","summary":"生物制药公司Theravance Biopharma Inc.的股价在盘前交易时段遭遇显著下滑,跌幅达到3.3%。此前,该公司宣布已与Zymeworks Inc.达成收购协议。根据协议条款,Zymeworks将以每股17美元的现金价格收购Theravance Biopharma的全部流通股,此外,交易还包含一项或有价值权安排。此项收购案为Theravance Biopharma的股东提供了直接的现金对价,并结合了基于未来特定里程碑达成情况而可能支付的额外价值。交易细节的公布通常会引起股价波动,此次盘前下跌正是市场对收购条款进行初步定价与权衡的直接体现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME","TBPH","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194792603","title":"Theravance Biopharma股东将就Ampreloxetine变现净收益的80%获得或有价值权","url":"https://stock-news.laohu8.com/highlight/detail?id=1194792603","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194792603?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:02","pubTimestamp":1782727338,"startTime":"0","endTime":"0","summary":"Theravance Biopharma公司宣布,其股东将有权获得一项或有价值权(CVR),该权利与Ampreloxetine资产变现所产生的净收益挂钩。具体而言,股东将有权分享该资产净收益的80%。这一安排旨在将未来潜在的价值创造直接回馈给公司股东。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TBPH","BK4007","ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160106816","title":"财报前瞻 |ZYMEWORKS INC (US)本季度营收预计降21.26%,机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1160106816","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160106816?lang=zh_cn&edition=full","pubTime":"2026-04-30 11:08","pubTimestamp":1777518491,"startTime":"0","endTime":"0","summary":"ZYMEWORKS INC 将于2026年05月07日(盘后)发布财报,市场关注收入走势与亏损收窄节奏及合作与管线进展对短期业绩的影响。市场一致预期本季度公司总收入约1,626.30万 美元,同比-21.26%;调整后每股收益约-0.19美元,同比+53.01%;EBIT预计-964.78万 美元,同比+82.77%,显示亏损有望收窄;毛利率与净利润/净利率的具体预测未披露。从近期覆盖公司的一致预期及财报快讯来看,看空观点在短期内占比较高。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"财报前瞻 |ZYMEWORKS INC (US)本季度营收预计降21.26%,机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115908800","title":"Zymeworks公司FRα靶向抗体偶联药物ZW191获美国FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=1115908800","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115908800?lang=zh_cn&edition=full","pubTime":"2026-03-30 18:01","pubTimestamp":1774864918,"startTime":"0","endTime":"0","summary":"Zymeworks Inc. (ZYME) 宣布,其针对叶酸受体α(FRα)的抗体偶联药物ZW191已获得美国食品药品监督管理局(FDA)授予的快速通道资格。这一认定将加速该候选药物的临床开发及审评进程。\n快速通道资格旨在促进针对严重疾病的创新疗法研发,使企业能与FDA进行更频繁的沟通,并可能获得优先审评和加速批准的机会。ZW191作为一款靶向FRα的下一代抗体偶联药物,在临床前研究中显示出显著的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173499227","title":"财报前瞻|ZYMEWORKS INC (US)本季度营收预计下降69.96%,关注合作收入波动","url":"https://stock-news.laohu8.com/highlight/detail?id=1173499227","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173499227?lang=zh_cn&edition=full","pubTime":"2026-02-23 10:47","pubTimestamp":1771814861,"startTime":"0","endTime":"0","summary":"ZYMEWORKS INC 将于2026年03月02日美股盘前发布最新季度财报,市场聚焦合作收入节奏与亏损幅度的变化。公司目前主营构成中,研究与发展合作收入贡献度最高,上季度该项收入2,761.40万美元,带动公司营收同比增长72.59%,显示合作回款与里程碑兑现对收入形成显著拉动。在收入构成高度集中的背景下,本季度营收一致预期为1,357.63万美元,同比下降69.96%,意味着市场对大额里程碑或预付款确认的可见度偏低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"财报前瞻|ZYMEWORKS INC (US)本季度营收预计下降69.96%,关注合作收入波动","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518351746","title":"Zymeworks(ZYME.US)获LifeSci Capital首次覆盖,给予优于大市评级, 目标价30.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518351746","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518351746?lang=zh_cn&edition=full","pubTime":"2025-03-11 20:41","pubTimestamp":1741696878,"startTime":"0","endTime":"0","summary":"Zymeworks(ZYME.US)获LifeSci Capital首次覆盖,给予优于大市评级, 目标价30.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11204148668017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518208789","title":"HC Wainwright & Co.:维持Zymeworks(ZYME.US)评级,由中性调整至中性评级, 目标价由12.00美元调整至13.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518208789","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518208789?lang=zh_cn&edition=full","pubTime":"2025-03-11 01:11","pubTimestamp":1741626683,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.:维持Zymeworks(ZYME.US)评级,由中性调整至中性评级, 目标价由12.00美元调整至13.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/11011148641372.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518278212","title":"Zymeworks Inc.盘中异动 快速跳水5.08%报11.39美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518278212","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518278212?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:10","pubTimestamp":1741615859,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时10分,Zymeworks Inc.股票出现异动,股价急速下跌5.08%。截至发稿,该股报11.39美元/股,成交量12.567万股,换手率0.18%,振幅3.50%。Zymeworks Inc.股票所在的生物技术行业中,整体涨幅为0.08%。Zymeworks Inc.公司简介:Zymeworks Inc 是一家临床阶段的生物制药公司,致力于下一代多功能生物治疗药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022105996403fe5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022105996403fe5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518228484","title":"Zymeworks Inc.2024财年实现净利润-1.23亿美元,同比减少3.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518228484","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518228484?lang=zh_cn&edition=full","pubTime":"2025-03-10 00:00","pubTimestamp":1741536055,"startTime":"0","endTime":"0","summary":"3月10日,Zymeworks Inc.公布财报,公告显示公司2024财年净利润为-1.23亿美元,同比减少3.36%;其中营业收入为76.30百万美元,同比增加0.38%,每股基本收益为-1.62美元。从资产负债表来看,Zymeworks Inc.总负债1.24亿美元,其中短期债务2.74百万美元,资产负债比为3.74,流动比率为0.04。机构评级:截至2025年3月10日,当前有7家机构对Zymeworks Inc.目标价做出预测,其中目标均价为20.71美元,其中最低目标价为12.00美元,最高目标价为30.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000120a268981f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310000120a268981f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517246181","title":"花旗:维持Zymeworks(ZYME.US)评级,由买入调整至买入评级, 目标价由18.00美元调整至19.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517246181","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517246181?lang=zh_cn&edition=full","pubTime":"2025-03-08 06:13","pubTimestamp":1741385596,"startTime":"0","endTime":"0","summary":"花旗:维持Zymeworks(ZYME.US)评级,由买入调整至买入评级, 目标价由18.00美元调整至19.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08061348605306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517169322","title":"Zymeworks Inc.盘中异动 早盘股价大跌7.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517169322","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517169322?lang=zh_cn&edition=full","pubTime":"2025-03-06 22:32","pubTimestamp":1741271543,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日22时32分,Zymeworks Inc.股票出现异动,股价大幅下挫7.02%。截至发稿,该股报12.26美元/股,成交量1.7717万股,换手率0.03%,振幅2.81%。Zymeworks Inc.股票所在的生物技术行业中,整体跌幅为0.66%。Zymeworks Inc.公司简介:Zymeworks Inc 是一家临床阶段的生物制药公司,致力于下一代多功能生物治疗药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223223a2628ff8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306223223a2628ff8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114803733","title":"异动解读 | ZYMEWORKS INC盘后大跌5.46%,业绩未达预期令市场失望","url":"https://stock-news.laohu8.com/highlight/detail?id=1114803733","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114803733?lang=zh_cn&edition=full","pubTime":"2025-03-06 05:42","pubTimestamp":1741210976,"startTime":"0","endTime":"0","summary":"ZYMEWORKS INC(ZYME.US)在周三盘后交易中股价大跌5.46%,引发了市场的广泛关注。\n\n根据公司最新季度财报,ZYMEWORKS INC当季每股亏损0.31美元,远高于分析师共识预期的0.03美元亏损。公司营收为3103万美元,也未达到分析师预期的4520万美元水平。\n\n业绩未达预期使得投资者对ZYMEWORKS INC未来增长前景感到失望,导致了公司股价在盘后交易中出现大幅下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | ZYMEWORKS INC盘后大跌5.46%,业绩未达预期令市场失望","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186593509","title":"赛梅克斯公司第四季度GAAP每股收益$(0.31)不及预期$(0.03),销售额$3103万不及预期$4520万","url":"https://stock-news.laohu8.com/highlight/detail?id=1186593509","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186593509?lang=zh_cn&edition=full","pubTime":"2025-03-06 05:10","pubTimestamp":1741209053,"startTime":"0","endTime":"0","summary":"相比去年同期每股亏损$,下降了93.75%。公司本季度报告销售额为$3103万,未达到分析师共识预期$4520万,相差31.35%。以上内容来自Benzinga Earnings专栏,原文如下:Zymeworks reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 933.33 percent. This is a 93.75 percent decrease over losses of $ per share from the same period last year. The company reported quarterly sales of $31.03 million which missed the analyst consensus estimate of $45.20 million by 31.35 percent. This is a 83.33 percent increase over sales of $16.93 ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"赛梅克斯公司第四季度GAAP每股收益$(0.31)不及预期$(0.03),销售额$3103万不及预期$4520万","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516765266","title":"Zymeworks Inc.盘中异动 下午盘快速下跌5.00%报12.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516765266","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516765266?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:18","pubTimestamp":1741025886,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时18分,Zymeworks Inc.股票出现异动,股价大幅跳水5.00%。截至发稿,该股报12.73美元/股,成交量18.0407万股,换手率0.26%,振幅5.22%。Zymeworks Inc.股票所在的生物技术行业中,整体涨幅为0.09%。Zymeworks Inc.公司简介:Zymeworks Inc 是一家临床阶段的生物制药公司,致力于下一代多功能生物治疗药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304021806abe67541&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304021806abe67541&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZYME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514011827","title":"Zymeworks Inc.盘中异动 早盘快速下挫5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514011827","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514011827?lang=zh_cn&edition=full","pubTime":"2025-02-26 00:21","pubTimestamp":1740500461,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日00时21分,Zymeworks Inc.股票出现波动,股价快速跳水5.02%。截至发稿,该股报13.25美元/股,成交量9.3355万股,换手率0.14%,振幅5.52%。Zymeworks Inc.股票所在的生物技术行业中,整体涨幅为0.53%。Zymeworks Inc.公司简介:Zymeworks Inc 是一家临床阶段的生物制药公司,致力于下一代多功能生物治疗药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600210196300a51&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022600210196300a51&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZYME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510335339","title":"Zymeworks Inc.盘中异动 早盘急速跳水5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510335339","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510335339?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:06","pubTimestamp":1739286379,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时06分,Zymeworks Inc.股票出现波动,股价快速下跌5.14%。截至发稿,该股报13.46美元/股,成交量3.2625万股,换手率0.05%,振幅3.74%。Zymeworks Inc.股票所在的生物技术行业中,整体跌幅为1.38%。Zymeworks Inc.公司简介:Zymeworks Inc 是一家临床阶段的生物制药公司,致力于下一代多功能生物治疗药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211230620a2420285&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211230620a2420285&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZYME","OCEA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509608259","title":"Zymeworks Inc.盘中异动 快速上涨5.06%报14.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509608259","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509608259?lang=zh_cn&edition=full","pubTime":"2025-02-06 04:54","pubTimestamp":1738788892,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日04时54分,Zymeworks Inc.股票出现波动,股价快速上涨5.06%。截至发稿,该股报14.96美元/股,成交量10.1962万股,换手率0.15%,振幅4.99%。Zymeworks Inc.股票所在的生物技术行业中,整体涨幅为1.91%。Zymeworks Inc.公司简介:Zymeworks Inc 是一家临床阶段的生物制药公司,致力于下一代多功能生物治疗药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206045453abc3cbf1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206045453abc3cbf1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZYME","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503625130","title":"Zymeworks Inc.盘中异动 早盘股价大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503625130","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503625130?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:50","pubTimestamp":1736952638,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时50分,Zymeworks Inc.股票出现异动,股价大幅拉升5.07%。截至发稿,该股报14.31美元/股,成交量2.4179万股,换手率0.04%,振幅2.72%。Zymeworks Inc.股票所在的生物技术行业中,整体涨幅为0.98%。Zymeworks Inc.公司简介:Zymeworks Inc 是一家临床阶段的生物制药公司,致力于下一代多功能生物治疗药物的发现、开发和商业化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152250389867406d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501152250389867406d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ZYME"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zymeworks.com","stockEarnings":[{"period":"1week","weight":-0.0578},{"period":"1month","weight":-0.0867},{"period":"3month","weight":-0.2008},{"period":"6month","weight":-0.0231},{"period":"1year","weight":0.6292},{"period":"ytd","weight":-0.1641}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.015},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.1483},{"period":"ytd","weight":0.0697}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Zymeworks Inc.于2022年6月根据特拉华州法律注册成立。该公司是一家全球性生物技术公司,管理着授权医疗资产组合并开发针对癌症、炎症和自身免疫性疾病的新型生物治疗产品线。其战略结合了特许权使用费聚合、战略收购和内部创新,并以其专有的多特异性抗体和抗体药物偶联物技术平台为支撑。","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":0.015488},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.056871},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.020874},{"month":4,"riseRate":0.666667,"avgChangeRate":0.045958},{"month":5,"riseRate":0.3,"avgChangeRate":0.007371},{"month":6,"riseRate":0.6,"avgChangeRate":-0.037508},{"month":7,"riseRate":0.4,"avgChangeRate":-0.043651},{"month":8,"riseRate":0.888889,"avgChangeRate":0.104131},{"month":9,"riseRate":0.444444,"avgChangeRate":0.038592},{"month":10,"riseRate":0.666667,"avgChangeRate":0.043198},{"month":11,"riseRate":0.777778,"avgChangeRate":0.135367},{"month":12,"riseRate":0.555556,"avgChangeRate":0.004939}],"exchange":"NASDAQ","name":"ZYMEWORKS INC (US)","nameEN":"ZYMEWORKS INC (US)"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ZYMEWORKS INC (US)(ZYME)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ZYMEWORKS INC (US)(ZYME)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ZYMEWORKS INC (US),ZYME,ZYMEWORKS INC (US)股票,ZYMEWORKS INC (US)股票老虎,ZYMEWORKS INC (US)股票老虎国际,ZYMEWORKS INC (US)行情,ZYMEWORKS INC (US)股票行情,ZYMEWORKS INC (US)股价,ZYMEWORKS INC (US)股市,ZYMEWORKS INC (US)股票价格,ZYMEWORKS INC (US)股票交易,ZYMEWORKS INC (US)股票购买,ZYMEWORKS INC (US)股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ZYMEWORKS INC (US)(ZYME)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ZYMEWORKS INC (US)(ZYME)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}